Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

The consensus estimate for Q2 2026 revenue is $493.07 billion, and the earnings are expected to come in at $44.83 per share.

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

A targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo met a key goal in a pivotal lung cancer study, but the companies also revealed an unspecified number of patient deaths, clouding ...

Investing.com - Daiichi Sankyo stock fell 4.5% on Friday after the Japanese pharmaceutical company maintained its core operating profit target at ¥350 billion despite strong sales performance.

Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, ...

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion Japanese ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new research ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen.